Akanda (NASDAQ:AKAN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Akanda (NASDAQ:AKAN) from a strong sell rating to a sell rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Akanda in a research note on Thursday, August 13th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Akanda Stock Down 3.5%

Akanda stock opened at $1.91 on Friday. The company has a fifty day moving average price of $3.97 and a two-hundred day moving average price of $9.95. Akanda has a 12 month low of $1.85 and a 12 month high of $78.90.

Akanda (NASDAQ:AKAN) last posted its quarterly earnings results on Wednesday, September 30th. The company reported ($5.90) earnings per share (EPS) for the quarter. The firm had revenue of $0.20 million for the quarter.

About Akanda

Akanda Corporation is an international medical cannabis company focused on the cultivation, processing, distribution and sale of cannabis products. Its activities have included medical cannabis flower, oils and other formulations intended for patients and healthcare markets.

The company has historically operated through businesses serving the European medical cannabis industry. Its operations have included cultivation and processing activities in Portugal, as well as CanMart, a United Kingdom-based importer and distributor of pharmaceutical-grade medical cannabis products.